Emerging Technologies for IO Targeting and Discovery
08
Aug
-
09
Aug
2023
When
Boston

USA
Where

In recent years, Immunotherapy has been at the forefront of oncology research. However, this has not been without issues. Some of which include applications to solid tumors, regulating biodistribution, and serious side effects. During this conference, we discuss tumor microenvironment modulation, improving delivery systems, novel approaches, and overcoming obstacles in IO. Join us for Cambridge Healthtech’s 2nd Annual Emerging Technologies for IO Targeting and Discovery conference. Here, experts and innovators come together to explore cutting-edge technologies and techniques for improving outcomes in the immuno-oncology space.

Similar Events

You May Like

Event

Cambridge Healthtech Institute

0/5
(0)

Cambridge Healthtech Institute – Your Life Science Network Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations.

08 - 09 Aug 2023
In-Person

Speakers and Delegates
Industry Experts and Thought Leaders

Principal Scientist/ Lab head
Board Trustee
Associate Principal Scientist
Chief Scientist, Cancer Immunology
Associate Professor
Director, Immuno-Oncology, Antibody-Drug Conjugates
Clinical Director of Neuro-oncology, Professor of Medicine
Chief Medical Officer
Chief Scientific Officer
Chief Scientific Officer
Chief Technology Officer, Founder
Manager, Scientific Analysis and Insights

Sponsors and Exhibitors
Brand, Media and Promotional Partners

WuXi AppTec

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients.

Biocytogen

Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities.

GenScript

Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific.

BPS Bioscience Inc.

BPS manufactures one of the largest selections of recombinant enzymes, neutralizing antibodies, inhibitor assay kits, lentiviruses and cell lines for drug discovery and continues to expand its drug discovery products.

Charles River Associates

Charles River Associates (CRA) is a global consulting firm specializing in litigation, regulatory, financial, and management consulting.

Sanyou Biopharmaceuticals Co., Ltd.

Sanyou Biopharmaceuticals Co., Ltd. is a leading international biological high-tech enterprise focusing on R&D and services of innovative antibody drugs.

Genscript Probio

The CDMO segment of the world's leading biotech company GenScript.

OmniAb, Inc.

The OmniAb discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics.

Selvita

Selvita is one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development.

Nona Biosciences

Nona Biosciences is a global biotechnology company committed to providing a total solution for partners worldwide, from academies, biotech startups to biopharma giants. The integrated antibody discovery services range from antigen preparation, animal

BostonGene

BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in

Organizer

Get emails from us

Thank you
Oops! Something went wrong